All News

Strategic Changes in the Pipeline

Today Avidin anounced that the company has made extensive recostruction of its projects. The R&D pipeline has changed and become updated accordingly (http://avidinbiotech.com/pipeline/). Q134R, Avidin’s

Approval to a Phase 1 Clinical Study

Approval to Initiate a Phase 1, First–In-Man, Clinical Study for Q134R Soneas Research Ltd. in collaboration with Avidin received approval to initiate a Phase 1,

BIO International Convention

Meet AVIDIN in San Francisco at the BIO International Convention between  June 6-9 2016.  Our CEO and Head of International Relations are looking forward to meet

New Product: Luciferin ethyl ester

Avidin has optimized the synthesis of  Luciferin ethyl ester, a membrane permeable analog of the primary substrate for the firefly luciferase. This reagent produces 30%